2型糖尿病治疗药物研究进展  

Advances in Therapeutics of Type 2 Diabetes Mellitus

作　　者：王涛 印晓星[2,3] 

机构地区：[1]徐州医科大学附属医院药学部,江苏徐州221002 [2]徐州医科大学药学院临床药理学教研室,江苏徐州221004 [3]江苏省新药研究与临床药学重点实验室,江苏徐州221004

出　　处：《药学进展》2016年第5期323-330,共8页Progress in Pharmaceutical Sciences

摘　　要：2型糖尿病(T2DM)是一种代谢障碍性疾病。传统抗糖尿病药物具有不同程度的副作用,如低血糖、胃肠道反应、体重增加、心血管风险等,因此开发作用于新靶点和新作用机制的T2DM治疗新药成为当前研究的热点。目前基于新靶点设计的糖尿病治疗新药有些已上市,且获得良好的降糖效果,但大部分药物仍处于临床或临床前研究阶段,其疗效和安全性有待进一步临床验证。综述传统抗糖尿病药物、T2DM药物新靶点及基于新靶点设计的抗糖尿病新药的研究进展。Type 2 diabetes mellitus（T2DM） is a metabolic disorder. Traditional anti-diabetics frequently lead to various side effects, such as hypoglycemia, gastrointestinal tract reaction, weight gain and cardiovascular risk. Therefore, development of T2 DM therapeutics acting on new target through new mechanism has become the focus of current research. Among those anti-diabetics designed against new target, some have reached the market and shown satisfactory hypoglycemic effect, whereas the large majority are still at the stage of pre-clinical and clinical development and subject to further investigations on their efficacy and safety. The recent progress in traditional anti-diabetics, new T2 DM targets and newly designed antidiabetics against those targets were reviewed.

关 键 词：2型糖尿病 传统抗糖尿病药物 作用机制 治疗靶点 

分 类 号：R977.15[医药卫生—药品]